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Abstract
Background: Investigation of the expression of an intestinal stem cell marker in esophageal adenocarcinomas
(EAC) with and without Barrett’s Esophagus (BE), with respect to a cancer stem cell (CSC) hypothesis.
Materials and methods: Expression of a putative intestinal stem cell marker LgR5 was analyzed in esophageal
cancer specimen (n = 70: 41 EAC with BE, 19 EAC without BE, and n = 10 esophageal squamous-cell carcinomas,
ESCC) and in the adenocarcinoma cell line OE-33. Ki-67 and Cdx-2 were co-labelled with LgR5 in double staining
experiments. Immunhistochemical expression results were confirmed by RT-PCR and correlated with tumor stage
and five-year survival rates.
Results: LgR5was found expressed in 35 of 41 (85%) EAC with BE and in 16 of 19 (81%) EAC without BE. By
contrast, LgR5 was not found to be expressed in ESCC. Quantification of immunolabeling showed 15% LgR5+ cells
in EAC with BE, 32% LgR5+ cells in adjacent BE and 13% in EAC without BE. Immunofluorescence double staining
experiments with LgR5 and Ki-67 revealed a subpopulation (~5%) of proliferating LgR+/Ki-67+ cells. On mRNA-
level, expression of LgR5 was higher in BE in comparison to EAC (p = 0.0159). High levels of LgR5 expression in BE
associated EAC were associated with poorer survival in univariate analysis.
Conclusion: The stem cell marker LgR5 is expressed in EAC, irrespective of association with BE, and appears to
have negative impact on survival. The subset of proliferating LgR5+ cells (<5%) might resemble rapidly cycling
CSCs, which needs to be substantiated in further investigations.
Introduction
Esophageal adenocarcinoma (EAC) is an entity of
increasing clinical importance, due to an unexplained
incidence rise among white males in the Western world
[1], and a dismal prognosis [2,3]. Chances for cure are
still limited to early, surgically resectable tumor stages,
prior to systemic dissemination of the disease. EACs
develop almost exclusively in the distal third of the eso-
phagus, under the chronically damaging effect of gastroe-
sophageal reflux [2,3]. Barrett’s esophagus (BE) - defined
as columnar-lined epithelium in the distal esophagus,
characterized by specialized intestinal mucosa (with gob-
let cells) - is regarded as a precancerous lesion, giving
rise to these tumors.
Malignant progression within BE is regarded to follow
a sequence of well-characterized histopathologic changes,
from intestinal metaplasia, over low-grade and high-
grade dysplasia/intraepithelial neoplasia towards invasive
adenocarcinomas [2,3]. However, not all esophageal ade-
nocarcinomas are associated with BE in surgical series
[4,5], and only a minority of patients with BE progress to
cancer, with an incidence of 0.5% per year [6]. These and
other findings have raised doubt about the relevance of
BE as precancerous lesion of EACs (e.g. [7]), stimulation
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the search for the cell population, from which EACs ori-
ginate and which is currently unknown.
Two cancer models have been put forward to explain
tumor heterogeneity and inherent differences of tumor-
regenerating capacity [8]. The clonal selection model of
carcinogenesis implies that a random solitary cell under-
goes malignant transformation, accumulates multiple
mutations and subsequently acquires a survival advan-
tage, which leads to clonal selection [9,10]. In contrast,
the cancer stem cell (CSC) hypothesis regards malignant
transformation as a process, occurring in a subset of
normal stem cells with pluripotent properties, which
underlie deregulation of self-renewal pathways [11,12].
Evidence is accumulating that most, if not all, malig-
nancies are driven by a cancer stem cell compartment
[8]. The existence of cancer stem cells would explain
why only a small minority of cancer cells is capable of
extensive proliferation within the tumor. Furthermore,
these cancer stem cells may be inherently resistant to
our current therapeutic approaches. It is important to
note that the two models are not mutually exclusive, as
CSCs themselves may undergo clonal evolution, as
already shown for leukaemia cells [13,14].
A stem cell hypothesis for BE has also been put for-
ward by the group around Spechler [13]. It has been
proposed that specialized intestinal metaplasia could
arise from a change in the differentiation pattern of
stem cells that might either reside in the esophagus or
which might be recruited to the esophagus from the
bone marrow [13]. A putative intestinal stem cell mar-
ker has been proposed to be potentially implicated in
carcinogenesis of BE and EAC, but have so far not been
thoroughly investigated. Leucine-rich-repeat-containing
G-protein-coupled receptor (LgR5) has been shown to be
associated with intestinal stem cell properties [15-18].
The aim of our study was to investigate expression of
this putative intestinal stem cell marker in esophageal
adenocarcinomas (EAC) with and without associated
intestinal metaplasia (BE) as well as associated BE and
squamous cell carcinomas. We aimed to give an indica-
tion for the carcinogenic process of EACs with respect
to a cancer stem cell (CSC) hypothesis.
Materials and methods
Patients and Tumor Specimen
Surgical specimen from altogether 70 patients having
undergone primary surgical resection for esophageal
cancer between January 2001 and June 2004 with com-
plete (R0) resection, were included in our study. Patients
with preoperative antineoplastic therapies (chemoradia-
tion/chemotherapy) were excluded.
The material was archival formalin-fixed, paraffin-
embedded tissue from routine histopathologic work-up.
Formalin-fixation and paraffin-embedding had been
performed under standardized conditions. The material
had been stored with permission of the local ethics
committee, after informed consent obtained from the
patients prior to surgical resection.
There were n = 41 esophageal adenocarcinomas (EAC)
with associated Barrett’s esophagus (BE), n = 19 EAC
without BE and n = 10 esophageal squamous-cell carci-
nomas (ESCC) of the esophagus (which were included as
negative controls). EAC without BE was defined based on
clinical information (endoscopic evidence of Barrett’s
mucosa), work-up of all tumor blocks (specialized intest-
inal metaplasia) and Cdx-2 staining which is regarded to
have a 70% sensitivity [19]. Of note, EAC were tumors in
the distal esophagus (AEG type I tumors, according to
the classification by Siewert and Stein, 1998, Br J Surg
[20]), and explicitly not localized at the level of the ana-
tomic gastric cardia (AEG type II tumors). The AEG type
II adenocarcinoma is a tumor entity on its own and must
be discussed differently.
Follow-up data were obtained from our local tumor
registry of Lower Frankonia/Germany and was complete
(100%) for all patients. In this tumor registry, data are
stored also with permission obtained from the patients
and due to the regulation of the local ethics committee.
Mean follow-up was 29 months ± 17.6 standard devia-
tion. Tumor and patient characteristics are summarized
in Table 1 and 2.
Histopathologic Analysis, Tumor Staging and Definition of
Barrett’s mucosa
Tumor blocks of paraffin-embedded tissue were selected
by two experienced gastrointestinal pathologists (Stefan
Kircher, Stefan Gattenlöhner), evaluating the routine H.
E. stained sections. Sections from all available tumors
underwent intensive histopathologic assessment, blinded
to the prior histopathology report. H.E. stained sections
were analyzed with respect to tumor infiltrated areas
(EAC/ESCC), stromal areas and infiltrating immune
cells. Tumor staging was performed according to the 6th
edition of the TNM staging system by the UICC/AJCC
of 2002 [21]. Grading was performed according to
WHO criteria [22]. Tumor characteristics (UICC stage,
pT-categories, pN-categories, cM-categories, number of
removed lymph nodes, number of tumor infiltrated
lymph nodes, residual tumor status, localization) and
patient characteristics were collected in a database
(EXCEL, Microsoft).
Barrett’s muscosa was defined as specialized intestinal
metaplasia, with goblet cells [2,3]. In addition, immuno-
histochemistry with Caudal type homeobox transcription
factor 2 (Cdx-2), which is suggested as early marker for
intestinal metaplasia [23] with a known sensitivity of
70% [19], was used to identify tiny foci of intestinal
metaplasia. Furthermore, different degrees of high-grade
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and low-grade intraepithelial neoplasia within Barrett’s
mucosa were assessed. EAC were classified as “EAC
with BE”, when at least tiny foci of intestinal metaplasia
were found due to Cdx-2 staining. EAC were classified
as “EAC without BE”, when the pathologists could not
find intestinal metaplasia on any of the tumor blocks.
Immunohistochemical and immunofluorescence staining
Staining for LgR5, Cdx-2, and Ki-67 was performed on
serial sections of 2 μm thickness. Tissue sections were
cut from formalin-fixed paraffin-embedded (FFPE)
blocks on a microtome and mounted on adhesive
microscope slides (Hartenstein, Wuerzburg, Germany).
For immunohistochemistry, unconjugated polyclonal
LgR5 (rabbit), and isotype control antibodies (mouse,
rabbit) were purchased from Abcam (Cambrige, UK).
The unconjugated mouse monoclonal Cdx-2 antibody
was obtained from Biogenex (San Ramon, USA) and the
unconjugated mouse monoclonal Ki-67 antibody was
purchased from Acris (Hiddenhausen, Germany). The
secondary antibody used for immunofluorescence double
staining of Ki-67 was a fluoresceinisothiocyanat (FITC)-
conjugated AffiniPure donkey-anti-mouse IgG, used at
1:200 dilution (Jackson ImmunoResearch Laboratories
Inc., Suffolk, England). The secondary antibody for LgR5
was a Cy3-conjugated AffiniPure donkey-anti-rabbit IgG
(Jackson ImmunoResearch), used at 1:200 dilution.
Normal colon tissue was used as positive control for
LgR5 expression [24,25]. The colon tissue had undergone
the same processing, like the esophageal cancer specimen
(normal formalin-fixed, paraffin-embedded tissue from
colon resections for benign conditions - normal colon
mucosa adjacent to polyps or diverticular disease).
Cell Culture
We analyzed LgR5 expression in cells (1 × 104) from the
esophageal adenocarcinoma cell line OE-33 (Sigma-
Aldrich, Steinheim, Germany) in cytospins as additional
positive control for LgR5 expression. This cell line is the
only commercially available adenocarcinoma cell line of
the lower esophagus (Barrett’s metaplasia) and was estab-
lished from a 73-year-old female patient. The tumor was
identified as pathological stage IIA (UICC) and showed
poor differentiation. Using RT-PCR we tested negative
Table 1 Clinicopathological characteristics of the EAC study population with BE
Characteristics Patients
(n = 41)
LgR5
Barrett’s esophagus*
p-value LgR5
Barrett’s EAC
p-value
low high low high
Age (y) .100 .051
<66 21 (51%) 10 (48%) 11 (52%) 4 (19%) 17 (81%)
≥66 20 (49%) 4 (20%) 16 (80%) 10 (50%) 10 (50%)
Gender .074 .673
Male 34 (83%) 14 (41%) 20 (59%) 11 (32%) 23 (68%)
Female 7 (17%) 0 (0%) 7 (100%) 3 (43%) 4 (57%)
Histological Grading .305a .083a
G1 11 (27%) 6 (55%) 5 (45%) 6 (55%) 5 (45%)
G2 16 (39%) 5 (31%) 11 (69%) 6 (37%) 10 (63%)
G3/4 14(34%) 3 (21%) 11 (79%) 2 (14%) 12 (86%)
Depth of invasion .481b .155b
pT1 10 (24%) 4 (40%) 6 (60%) 6 (60%) 4 (40%)
pT2 18 (44%) 7 (39%) 11 (61%) 6 (33%) 12 (67%)
pT3 6 (15%) 1 (17%) 5 (83%) 1 (17%) 5 (83%)
pT4 7 (17%) 2 (28%) 5 (72%) 1 (14%) 6 (86%)
Lymph node metastases .001 .0154
pN0 15 (37%) 10 (67%) 5 (33%) 9 (60%) 6 (40%)
pN1-3 26 (63%) 4 (15%) 22 (85%) 5 (19%) 21 (81%)
UICC stage .481c .155c
UICC I 9 (22%) 4 (44%) 5 (56%) 2 (22%) 4 (78%)
UICC II 19 (46%) 7 (37%) 12 (63%) 7 (37%) 12 (63%)
UICC III 13 (31%) 3 (23%) 10 (77%) 5 (15%) 11 (85%)
UICC IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Median OS (m) 42 m 32 (n = 14) 24 (n = 27) 33 (n = 14) 28 (n = 27)
Abbrevations: EAC, esophageal adenocarcinomas; BE, Barrett metaplasia; y, years; G, grading; UICC, International Union against Cancer; R, residual tumor; OS,
overall survival; m, months. *Clinico-pathological features of BE are related to adjacent EAC.
aG1/2 vs. GT3/4; bpT1/2 vs. pT3/4; cUICC I/II vs. UICC III/IV.
von Rahden et al. Journal of Experimental & Clinical Cancer Research 2011, 30:23
http://www.jeccr.com/content/30/1/23
Page 3 of 11
for mycoplasma contamination of this cell line that was
provided to our laboratory in December 2009 by Sigma.
The cell line was cultured in RPMI-1640 medium, sup-
plemented with 10% Fetal Bovine Serum, 100 units/ml of
penicillin and 100 μg/ml of streptomycin. Cytospins of
the OE-33 cell line were fixed in acetone and dried for
10 minutes. Rehydration, blocking, and the staining pro-
cedure steps were the same as described for immunohis-
tochemistry of FFPE sections. Additionally, RT-PCR was
performed for LgR5 gene expression of OE-33 cells.
Double Staining Experiments (IF and IHC)
The sequential immunofluorescence (IF) double staining
(co-expression) was analyzed for LgR5 with Ki-67
expression. Sequential immunohistochemical (IHC) dou-
ble staining was performed for Cdx-2 and LgR5.
Processing of tissue and staining procedure
Serial tissue sections (2 μm thickness) were cut from
formalin-fixed paraffin-embedded (FFPE) blocks on a
microtome and mounted from warm water onto adhe-
sive microscope slides (Hartenstein, Wuerzburg,
Germany). Sections were deparaffinized in xylene and
ethanol and rehydrated in water. Heat induced epitope
retrieval (HIER) was performed with citrate buffer pH
6.0 (Dako, Hamburg, Germany). For immunofluores-
cence, slides were incubated in normal serum (2%) and
bovine serum albumin (BSA 0.5%) at room temperature
for 20 minutes to block non-specific binding. Subse-
quently, slides were incubated with the primary antibody
or control antibody overnight at 4°C in a humidified
chamber and with secondary FITC-conjugated antibody
for 30 minutes at room temperature. Slides were subse-
quently incubated with the second primary antibody
diluted in TBS plus 0.5% BSA overnight at 4°C in a
humidified chamber followed by incubation with sec-
ondary Cy3-conjugated antibody for 30 minutes at room
temperature in a humidified chamber. Slides were coun-
terstained with DAPI (4’,6-Diamidino-2-phenylindoldi-
hydrochlorid) (Sigma-Aldrich) and covered with
Polyvinyl-alcohol mounting medium (DABCO) (Sigma-
Aldrich) and analyzed using a Zeiss camera (Jena,
Germany). The photographed images - using the Meta-
morph software package (Visitron Systems, Puchheim,
Germany) - were imported into the Microsoft Office
Picture Manager.
For immunohistochemistry, the pretreatment proce-
dure (fixation, deparaffinization, rehydration, HIER, and
blocking) of the slides was the same as described for
immunofluorescence. Endogenous peroxidase activity
was quenched with 3% hydrogen peroxide. Endogenous
biotin activity was blocked using the avidin/biotin block-
ing kit (Vector Laboratories, Burlingame, CA, USA).
Slides were then incubated with the primary antibody
alone (LgR5, Cdx-2, and Ki-67) or with pre-incubated
(30 minutes) LgR5 blocking peptide (Abgent, San Diego,
CA, USA) and LgR5 antibody. After incubation with the
primary antibody the DAKO LSAB2 System, peroxidase,
was used. Slides were subsequently incubated for
5 minutes in DAB (3,3’-diaminobenzidine) (Biogenex)
counterstained with hemalaun and mounted with
Glycergel (Dako). For immunohistochemical double
staining, we first used an alkaline phosphatase (AP)-con-
jugated AffiniPure Donkey anti-mouse Ab followed by
20 minutes of incubation with Fast Red (Dako). After
incubation with the second primary antibody, we used a
horseradish peroxidase (HRP)-conjugated AffiniPure
Donkey anti-rabbit IgG (Jackson ImmunoResearch) fol-
lowed by 5 minutes of incubation with DAB (Biogenex).
Cytospins were fixed in acetone and dried for 10 min-
utes. Rehydration, blocking, and the staining procedure
was the same as described for immunohistochemistry of
FFPE sections.
Table 2 Clinicopathological characteristics of the EAC
study population (with and without BE)
Characteristics Patients
(n = 60)
LgR5
EAC
p-value
low high
Age (y) .069
<66 30 (50%) 10 (33%) 20 (67%)
≥66 30 (50%) 18 (60%) 12 (40%)
Gender 1.00
Male 52 (87%) 24 (46%) 28 (34%)
Female 8 (13%) 4 (50%) 4 (50%)
Histological classification .577a
G1 17 (28%) 11 (65%) 6 (35%)
G2 22 (37%) 11 (50%) 11 (50%)
G3/4 21 (33%) 6 (29%) 15 (71%)
Depth of invasion .259b
pT1 16 (27%) 11 (69%) 5 (31%)
pT2 26 (43%) 11 (42%) 15 (58%)
pT3 10 (17%) 4 (40%) 6 (60%)
pT4 8 (13%) 2 (25%) 6 (75%)
Lymph nodes metastasis .007
pN0 23 (38%) 16 (70%) 7 (30%)
pN1-3 37 (62%) 12 (32%) 25 (68%)
UICC stage .573c
UICC I 14 (23%) 10 (71%) 4 (29%)
UICC II 28 (47%) 11 (39%) 17 (61%)
UICC III 18 (30%) 7 (39%) 11 (61%)
UICC IV 0 (0%) 0 (0%) 0 (0%)
Median OS (m) 43 m 32 (n = 28) 24 (n = 32)
Abbrevations: EAC, esophageal adenocarcinomas; BE, Barrett metaplasia; y,
years; G, grading; UICC, International Union against Cancer; R, residual tumor;
OS, overall survival; m, months.
aG1/2 vs. GT3/4; bpT1/2 vs. pT3/4; cUICC I/II vs. UICC III/IV.
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Quantification of Immunohistochemistry and
Immunofluorescence
LgR5 and Ki-67 IHC was quantified in EAC with BE, in
the associated Barrett’s mucosa, as well as EAC without
BE. Quantification of immunoenzymatic staining of
intestinal metaplasia or tumor cells was performed ana-
lyzing six defined representative individual high power
fields (× 400) for each staining sample. Scoring was
done by means of cell counting. The results were
expressed as percentages (number of positive cells
within 100 counted tumor cells, %). Sections were evalu-
ated by two independent blinded investigators separately
and, in case of discrepancies, both evaluated the slides
simultaneously and made an agreement.
For each tumor section, quantification of immuno-
fluorescence double staining was performed by counting
Ki-67+ cells in six high power fields (400 × magnifica-
tion) in parallel with LgR5+. The proportion of Ki-67
positivity in counted LgR5+ cells was expressed in
percentages.
Real-time quantitative reverse transcription-PCR analysis
To analyze gene expression of LgR5 by RT-PCR, we
extracted total cellular RNA and performed cDNA
synthesis using the Absolutely RNA FFPE Kit and Affi-
nityScript QPCR cDNA Synthesis Kit from Stratagene
(Waldbronn, Germany). Areas of interest (only epithelial
regions) for each tissue section were manually microdis-
sected using a scalpel blade. For both groups (BE and
EAC without BE) equal amounts of tissue areas were
assessed (2 × 1.5 cm2 surface area per section, thickness
of 10 μm). RNA extraction and cDNA synthesis were
performed according to the manufacturer’s instructions.
For OE-33 cell line, after homogenization Diethyl pyro-
carbonate (DEPC)-75% ethanol was added to the lysate
to provide ideal binding conditions. Primers were
designed using the Primer Express software for primer
design to amplify short segments of 50-150 base pairs of
target cDNA. The LgR5 forward primer sequence was:
5’-TGCTGGCTGGTGTGGATGCG-3’; the LgR5 reverse
primer sequence was: 5’-GCCAGCAGGGCACAGAG-
CAA-3’. Matched human esophageal cDNA was pur-
chased by BioChain (Hayward, CA, USA) as control.
The housekeeping gene Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used for relative quantifi-
cation and cDNA quality control. The GAPDH forward
primer sequence was: 5’-ATCCCATCACCATCTTC-
CAGG-3’; the GAPDH reverse primer sequence was: 5’-
CGCCCCACTTGATTTTGG-3’. All PCR reactions were
carried out with a DNA Engine Opticon 2 System (MJ
Research, Biozym, Oldendorf, Germany). Total RNA
was reversely transcribed into cDNA according to the
manufacturer’s manual. Each PCR reaction was per-
formed in 25 μl volume containing 12.5 μl the Sensi
Mix (Peqlab, Erlangen, Germany), 0.5 μl SYBR Green,
10 pmol/μl forward primer, 10 pmol/μl reverse primer,
1 μl template DNA (150 ng) and 9 μl peqgold RNAse
free water. Initial denaturation at 95°C for 10 minutes
was followed by 38 cycles of a denaturation step at 95°C
for 15 seconds, an annealing step at 60.9 °C for 30 sec-
onds, and an extension step at 72°C for 40 seconds. To
confirm amplification specificity, the PCR products from
each primer pair were subjected to a melting curve ana-
lysis. Negative controls without template were produced
for each run.
Quantification data were analyzed using the LightCy-
cler analysis software. Reproducibility was confirmed by
independent PCR repeated twice. The average threshold
cycle (Ct) value was calculated as the cycle number at
which the fluorescence of the reporter reaches a fixed
threshold. The difference (ΔCt) between the average Ct
values of the samples in the target wells and those of
the housekeeping gene (GAPDH) was assessed, followed
by calculation of the difference between the average ΔCt
values of the tumor samples for each target and the ΔCt
value of the normal tissues for that target (ΔΔCt). The
relative quantification value, fold difference, is expressed
as 2-ΔΔCt.
Statistical analysis
Statistical analysis was performed with MedCalc Soft-
ware, Version 11.3.2 (Mariakerke, Belgium). All values
were expressed as Median ± Interquartile Range (IQR)
because a normal distribution of gene and protein
expression could not be confirmed by the D’Agostino-
Pearson test. Therefore, the Median value was chosen to
divide patients in two different groups. Survival time
was determined as the time from tumor resection to
tumor conditional death and as the time from tumor
resection to time of obvious recurrence. The overall sur-
vival (OS) time in association with LgR5 expression was
estimated using the Kaplan-Meier method [26]. To ana-
lyze differences in the overall/tumor related survival
among patients after successful (R0) curative surgical
resection for EAC patients were divided into two sub-
groups (dichotomous variables). Median cut-off value
for either high or low expressors was set at 33% for
LgR5 expression in BE (n = 41), 15% for LgR5 expres-
sion in adjacent EAC (n = 41), and 15% for LgR5
expression in all EAC (n = 60); univariate analysis of
significance for LgR5 expression differences in survival
curves was evaluated with the log rank test. Multivariate
with the Cox Proportional Hazards Model [27] was per-
formed including all parameters that were found to be
significant on univariate analysis. Fisher’s exact test was
used to investigate the relation between two categorical
variables. Data were analyzed using the non-parametric
Mann-Whitney U test or Kruskal-Wallis test when more
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than 2 groups were compared. P values of less than 0.05
were regarded statistically significant.
Results
LgR5 Immunohistochemistry
Immunohistochemistry against the putative intestinal
stem cell marker LgR5 showed positive stainging in 85%
(35 of 41) of the specimen of patients with EAC with
BE, and 84% (16 of 19) in EAC without BE (p = n.s). No
LgR5 expression was found in specimen with esophageal
SCC.
No expression of the putative stem cell marker (LgR5)
was detected in normal esophageal squamous cell
epithelium, adjacent to the tumor.
Normal colon mucosa (used as positive control)
showed the typical staining pattern of LgR5 (Figure 1a
and 1b), as they stained the well-described putative
colon mucosa stem cells, located at the basis of the
crypts, or the transit amplifying zone, which are
regarded to resemble the stem cell niche [24,25].
Quantification of LgR5 Immunohistochemistry
Furthermore, we analyzed positivity of all counted cells
according to the precursor lesion and tumor entity. LgR5
expression was significantly upregulated in BE (n = 41,
Median 33%, IQR 14.75% - 45.0%; 95% CI 24.761 -
39.954%; p < 0.05; Figure 2a) but was decreased in adja-
cent EAC (n = 41, Median 15%, IQR 13.0% - 18.0%; 95%
CI 13.761 - 17.0%; p < 0.05; Figure 2a) and EAC without
BE (n = 19, Median 13%, IQR 4.75% - 23.0%; 95% CI
6.346 - 22.436%; p < 0.05; Figure 2a; p < 0.05 for LgR5
expression of BE with adjacent EAC and EAC with and
without BE). No differences of LgR5 expression were
found between different degrees in high-grade and low-
grade intraepithelial neoplasia within Barrett’s mucosa
and did not significantly differ from EAC. Median LgR5
expression of all EACs (n = 60) was 15%, IQR 11.0% -
18.0%; 95% CI 13.0 - 16.061%. For adenocarcinomas
without BE, the results of LgR5 expression were compar-
able with the lower expression levels of adenocarcinomas
from BE (Figure 2a, Table 1 and 2). Stainings from the
OE-33 adenocarcinoma cancer cell line in cytospins
served as additional positive controls for LgR5 expression
and showed 25% positive cells (Figure 2b). Preincubation
with LgR5 blocking peptide completely abolished LgR5
immunoreactivity (Figure 1b).
Figure 2c and 2d demonstrate representative exam-
ples of LgR5 and Cdx-2 staining in early BE. We con-
firmed areas analyzed for LgR5 expression of BE by
means of immunohistochemical co-labelling with Cdx-
2 (Figure 2d). Staining was observed in putative stem
cell niches at the bottom of BE and EACs (Figure 2e).
LgR5 Gene Expression Analysis on mRNA Level
To confirm the results of the immunohistochemical
staining, gene expression of LgR5 in human EAC was
assessed on mRNA level by means of semiquantitative
RT-PCR. EAC associated BE (Median 3.5-fold differ-
ence compared to normal tissue; IQR 3.025 - 3.725-
fold difference; n = 7) exhibited LgR5 gene expression
which was significantly (p = 0.0159) higher in compari-
son to EAC without BE (Median 1.4-fold difference
compared to normal tissue; IQR 0.900 - 1.650-fold dif-
ference; n = 8; Figure 2f). These results confirmed
increased LgR5 expression in BE adjacent to EAC and
significantly decreased expression of LgR5 in EAC
without BE as observed by immunohistochemistry.
LgR5 RT-PCR results of the OE-33 adenocarinoma cell
line showed 4.8-fold difference compared to normal
tissue.
LgR5 Expression in Relation to Proliferative
Activity (Ki-67+)
For further investigation of the adoptive role of LgR5 in
BE and its relation to potentially cancer-initiating cells
in early BE, we analyzed proliferation status of LgR5
expressing early Barrett cells. A small subset of LgR5+
cells were Ki 67+ (proportion of Ki-67 positivity in
counted LgR5+ cells was <5%). As shown in Figure 3a
and 3b, Ki-67 was co-expressed with only a small subset
of LgR5+ cells in areas which were associated with early
BE (Cdx-2 positivity was observed in serial sections)
(Figure 3a, representative example of n = 41 BE and
associated adenocarcinomas) and OE-33 cells (Figure
3b). Vice versa, most of LgR5+ Barrett cells did not pro-
liferate, as they did not exhibit nuclear staining with the
proliferation marker (Ki-67-). In contrast, we analyzed a
dominant population of proliferating Ki-67+/LgR5- cells
(Figure 3a). Although down-regulated in EAC with BE,
as well as EAC without BE, we confirmed a minority of
proliferating cells in Cdx-2 negative (Cdx-2-) areas (data
not shown).
bLgR5 (colon) a
* *** *
Figure 1 Immunohistochemical staining of LgR5 (membranous
staining pattern, brown) in normal colon tissue. Normal colon
mucosa (asterisk) showed the typical staining pattern as they
stained the well-described putative colon mucosa stem cells,
located at the basis of the crypts, or the transit amplifying zone,
which are regarded to resemble the stem cell niche (arrows).
Original magnification, × 200 (a) and × 400 (b).
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d2 = Adjacent adenocarcinoma to BE (n=41)
1 = Barrett s esophagus (BE) (n=41)
3 = Adenocarcinoma without BE (n=19)
4 = Squamous-cell carcinomas (n=10)
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Figure 2 Immunohistochemical analysis, staining and gene expression of LgR5. In comparison to BE (1) a significantly (p < 0.05) decreased
expression of LgR5 was observed in associated EACs (2) and EACs without BE (3). ESCC showed no LgR5 expression (4). Analysis refers to
percentages of positivity of all counted cells. Grey lines show 95% confidence intervals. Statistically significant values from BE to EACs and ESCC
are indicated with asterisks (a). LgR5 staining in cytospins from the OE-33 adenocarcinoma cancer cell line served as additional positive control
(left, top) and showed 25% positive cells; Preincubation with LgR5 blocking peptide completely abolished LgR5 immunoreactivity (right, bottom)
(b). Increased expression of LgR5 (c) was observed in early BE (arrows). Adjacent normal tissue stained negative for LgR5 (asterisk). Single staining
of LgR5 in BE was confirmed by immunohistochemical double staining (d), showing Cdx-2 (nuclear staining pattern, Fast red) and LgR5
(membranous staining pattern, brown). Significantly decreased LgR5 expression was observed in adenocarcinomas compared to BE. Staining was
observed in putative stem cell niches at the bottom of EACs (arrows) (e). Original magnification × 200. Gene expression of LgR5 in human BE
and EAC (x-fold difference mRNA). LgR5 gene expression in BE-associated EAC (1) was significantly (p = 0.0159) higher in comparison to EAC
without BE (2). Grey lines show 95% confidence intervals. Statistically significant value is indicated with an asterisk. Normal tissue is considered as
one-fold (f).
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Prognostic Effect of LgR5
To analyze survival differences of patients after successful
(R0) curative surgical resection for EAC with and without
BE, patients were divided into two subgroups as
described above (dichotomous variables). Lymph node
metastasis (pN+, p < 0.0001, Hazard Ratio (HR) =
12.1940, 95% CI = 5.9509 - 24.9867), pT-category (pT3/
4, p < 0.0001, HR = 3.8447, 95% CI = 1.5309 - 9.6553)
and grading (G3/4, p < 0.0001, HR = 4.0652, 95% CI =
1.7123 - 9.6514) were shown to be unfavorable factors in
univariate analysis in the whole population of all EACs
(n = 60). Survival in subgroup with high LgR5 expression
in BE (n = 41, p = 0.0278, HR = 3.5145, 95% CI = 1.5050
- 8.2073, Figure 4a), adjacent EACs (n = 41, p = 0.039,
HR = 2.8408, 95% CI = 1.2496 - 6.4582) and all EACs (n
yy= 60, p = 0.0325, HR = 2.4175, 95% CI = 1.1719 -
4.9872, Figure 4b) was significantly poorer in comparison
to the subgroup of patients with low expression of LgR5
(Table 1 and 2). Data suggest that LgR5 expression in BE
and adjacent EACs is associated with clinical pathological
features which may predict worse clinical outcome of
related (adjacent) adenocarcinomas. Multivariate analysis
using the Cox Proportional Hazards Model demonstrate
lymph node metastasis and grading but not LgR5 expres-
sion as independent prognostic factors in all (n = 60)
EACs (LN positive: Exp (b) 9.1861; 95% CI of Exp (b)
2.0665 - 40.8346; p = 0.003746. Grading G3/4: Exp (b)
2.2593; 95% CI of Exp (b) 1.0171 - 5.0186; p = 0.4643).
Discussion
Similar to other solid tumor entities [8], a stem cell
hypothesis has been proposed for Barrett’s esophagus
(BE) and its association with EAC [13]. However, this
hypothesis has not undergone thorough investigation so
far. An intestinal stem cell marker, LgR5 has been pro-
posed [13], but have also not been thoroughly addressed
in histogenetic studies.
Our results of LgR5 expression in EAC with and with-
out BE, as well as the adjacent Barrett mucosa suggest
that LgR5 might be a promising marker to further
address the stem cell hypothesis. In esophageal SCC - as
expected no LgR5 expression was found, which is due
to the fact that ESCC is not derived from an intestinal
(glandular) type epithelium.
Several studies have already focused on the effects of
different LgR5 expression in the context of tumor devel-
opment and progression. LgR5 has been demonstrated
to be involved in the pathogenesis of different human
cancer entities, including hepatocellular carcinoma [28],
basal cell carcinoma [29], endometrial cancer [30], colon
cancer and ovarian cancer [31]. Interestingly, LgR5 was
identified to be expressed on crypt stem cells (precursor
cells) as well as lesions which had progressed to cancer
[15,32]. One previous study has demonstrated expres-
sion of LgR5+ in BE and EAC [33].
Our results of significant upregulation of LgR5 in BE
and downregulation in associated EAC are in concor-
dance to results in other solid tumor entities. In the
endometrium, high expression of LgR5 is observed
during the initial stages of tumorigenesis, but down-
regulation of LgR5 is described for fully developed
tumors [30]. This is well in line with our findings in
EAC. Our results might be explained with the clonal
selection model of carcinogenesis, which proposes that
there is a subsequent clonal selection of putative stem
cells [8]. The expression profile of LgR5 in EAC with-
out BE was comparable with the result of EAC with
BE.
According to a longstanding cancer model, known as
the ‘clonal evolution model’, tumors arise from normal
cells that mutate and generate abnormal offspring that
do also mutate, forming a mass of genetically varied
cancer cells. However, there has been a new wave of
interest in an alternative explanation - that tumors are
initiated and driven by a single, abnormal type of cancer
stem cell, resulting in a population of genetically identi-
cal tumor cells. This is the ‘cancer stem cell hypothesis’
(CSC) which is currently intensively discussed in the
oncologic literature [8].
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Figure 3 Co-expression of LgR5 with Ki-67 in BE and OE-33
cells by immunofluorescence double staining. Images
demonstrate a representative example of LgR5 co-expression with
Ki-67 in early BE showing positivity for a small subset of LgR5+ cells
with Ki-67+ (arrows). In contrast, a dominant population of
proliferating (Ki-67+) Barrett cells were LgR5-, which may drive
multi-step carcinogenesis (asterisks). Vice versa, most of LgR5+
Barrett cells were Ki-67- (asterisks). Proliferating LgR5+ OE-33 cells
(arrows) are shown below (b). FITC green Fluoresceinisothiocyanat,
Cy3 red, and DAPI 4’,6-Diamidino-2- phenylindoldihydrochlorid blue.
Top (a), Calibration bar represents 50 μm. Bottom, Calibration bar
represents 25 μm (a and b). Case demonstrates area of
magnification.
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Our double-staining experiments, with the putative
stem cell marker LgR5 and the proliferation marker Ki-
67 demonstrated three different cell populations. First, a
substantial fraction of cells was found to express the
putative stem cell marker LgR5, which were not cycling
(LgR5+/Ki-67-). These might be regarded as quiescent
stem cells, or postmitotic dedifferentiated cells. Sec-
ondly, there was a major cellular compartment in BE as
well as EAC, which showed no expression of the puta-
tive stem cell marker LgR5, but which were actively
cycling (LgR5-/Ki-67+). This result might be interpreted
in line with the clonal selection theory. If LgR5 marks
stem cells, there are many of LgR5 negative non-stem
cells, which are nevertheless cycling. Therefore a combi-
nation of clonal selection and cancer stem cell model, as
previously suggested by others [8,34] might be applied.
Moreover, we found a small subpopulation of cells
within BE as well as esophageal AC, which expressed
the putative stem cell marker LgR5, and which were
actively cycling (LgR5+/Ki-67+). This population
accounted for approximately 5% of BE. According to
our hypothesis, that the intestinal stem cell marker
LgR5 might also be suited to identify cancer stem cells,
these might be the actively cycling Barrett (cancer) stem
cells.
Our findings are in line with current cancer models
[8] suggesting an integration of the CSC hypothesis and
the clonal selection model [34]. CSCs may undergo clo-
nal selection, thereby forming a second generation of
CSCs, which may itself give rise to a tumor [8].
We assume that at least a portion of the proliferating
population consists of LgR5+ Barrett cells and these
results are compatible with the view that a minority
population of Barrett cells is able to proliferate and con-
tribute to the numbers of a larger Barrett cell population
with a modified capacity for proliferation. Such a situa-
tion would be analogous to that found in normal hemo-
poietic differentiation, where a minority population of
stem cells proliferates and gives rise to a large popula-
tion of progeny, most of which have lost stem cell
properties.
Finally, adenocarcinoma in BE may contain a cellular
subcomponent that retains key stem cell properties
[13,33,35,36]. Chronic activation of LgR5 expressed by
BE in these putative pluripotent cancer-initiating cells
may sustain inflammation responses, mediate resistance
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Figure 4 Kaplan-Meier survival curves. Overall survival curves calculated by Kaplan-Meier method in Barrett-associated EACs (Figure 4a) and
the whole population of all EACs (Figure 4b), respectively. Survival of patients with EAC was better when BE showed low LgR5 expression
compared to high LgR5 expression. This was shown for BE in association with EAC (p = 0.0278) (a) and the whole population of EACs (b),
respectively (p = 0.0325). The times of the censored data are indicated by short vertical lines.
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to apoptosis and promote further progression of the
metaplasia - intraepithelial neoplasia - carcinoma
sequence. Therefore targeting of LgR5 signalling might
be a potential mechanism to abrogate this inflamma-
tion-mediated effect in tumor progression. This may be
the reason for the higher expression of LgR5 in precan-
cerous cells of BE, in comparison to cells of invasive
AC. LgR5 signalling may therefore play a biological role
in potentially cancer-initiating BE cells.
Although Barrett’s esophagus (BE) is regarded as pre-
cancerous lesion of esophageal adenocarcinomas (EAC),
some doubts have been raised regarding this association
[7]. A substantial proportion of adenocarcinomas in the
distal esophagus were not associated with Barrett
mucosa. There are different potential explanations
regarding pathogenesis and origin of these EAC without
Barrett.
- First, AC without BE may have originated within a
Barrett mucosa, which may have been previously
destroyed (’overgrown’) by the tumor [37,38]. It has
been suggested, that neoadjuvant therapy may result in
‘unmasking ’ of the previously ‘overgrown’ Barrett
mucosa.
- Moreover, AC without BE may have originated in
very small spots of (ulta short segment) Barrett mucosa
or cases in which intestinal metaplasia was not stained
with Cdx-2 [19].
- Finally AC without BE may have originated from
another cell type, which might be the putative cancer
stem cell.
A prognostic effect of LgR5 expression on protein
level (IHC) was shown on univariate survival analysis.
Patients with a high percentage of LgR5+ cells (>33%)
exhibited a worse prognosis, in comparison to patients
with lower LgR5+ staining. This was shown for the
whole population of all patients with EAC under investi-
gation, a result which is in line with previously pub-
lished results [33]. We have furthermore shown, that a
similar prognostic effect could be seen, when LgR5
expression was examined in a similar fashinon in adja-
cent Barrett’s mucosa in EACs with BE. This result has
not been decribed before and may be regarded due to
the effect of ‘field cancerization [39].
Taken together, LgR5-expression was found in a sub-
set of proliferating LgR5+ intestinal cells, within BE,
within BE-associated EAC as well as EAC without BE.
Persistent activation of LgR5 in intestinal metaplasia and
EACs may thus sustain multi-step carcinogenesis. Our
findings seem to be very well in line with current under-
standing of carcinogenesis according to an integrated
model of the CSC hypothesis and the clonal evolution
theory [8]. Further investigations are required to sub-
stantiate these findings.
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